Biology Faculty Articles

Title

Daptomycin. Fresh from the Pipeline

Document Type

Article

Publication Date

12-1-2003

Publication Title

Nature Reviews Drug Discovery

ISSN

1474-1776

Abstract

In September 2003, daptomycin (Cubicin; Cubist Pharmaceuticals) — the first member of a new class of antibiotics — was approved by the US FDA for the treatment of infections caused by Gram-positive bacteria. Will its ability to treat infections resistant to many current antibiotics lead to significant market success?

This document is currently not available here.

Find in your library

Share

COinS